Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayastha D, Woodman RC, Hofmann W-K,
Hehlmann R, Hochhaus A, Müller MC: MDR1 expression predicts outcome of Phþ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. Leukemia (2014), 1-8. PMID: 24472814

Busch A, Zeh D, Janzen V, Mügge L-O, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M: Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. British Society for Immunology, Clinical and Experimental Immunology (2014), 177, 439–453.
PMID: 24712857

Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, Müller MC, Giehl M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A: The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. (2014)  93, 81 - 88. doi: 10.1007/s00277-013-1964-1.
PMID: 24281161

Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Dabler J, Malchers F, Schottle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmuller J, Becker C, Nurnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sanger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansen S, Haas SA, Yatabe Y, Thomas RK: CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery (2014). 415-422.
PMID: 24469108

Frietsch JJ, Dornaus S, Neumann T, Scholl S, Schmidt V, Kunert C, Sayer HG, Hochhaus A, La Rosée P: Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: Case series with focus on 5-azacytidine and literature review. European Journal of Histochemistry (2014). doi: 10.1111/ejh.12311. PMID: 24635656

Frietsch JJ, Kastner C, Grunewald TGP, Schweigel H, Nollau P, Ziermann J, Clement JH, La Rosée P, Hochhaus A, Butt E: LASP1 is a novel BCR-ABL substrate and a phosphorylationdependent binding partner of CRKL in chronic myeloid leukemia. Oncotarget (2014). PMID: 24913448

Gale RP, Hochhaus A: OBITUARY Nicole Muller-Bérat Killmann 1932–2014 Leukemia pioneer. Leukemia (2014) 28, 727–728. PMID:24714344

García-Albéniz X, Gallego R, Hofheinz RD, Fernández-Esparrach G, Ayuso-Colella JR, Bombí JA, Conill C, Cuatrecasas M, Delgado S, Ginés A, Miquel R, Pagés M, Pineda E, Pereira V, Sosa A, Reig O, Victoria I, Feliz L, María de Lacy A, Castells A, Burkholder I, Hochhaus A, Maurel J: Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
World J Gastroenterol. (2014) 20, 15820-9. doi: 10.3748/wjg.v20.i42.15820.
PMID: 25400468

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann W-K, Hochhaus A, Müller MC: Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica (2014). doi:10.3324/haematol.2013.096537. PMID: 24837466

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann W-K, Hochhaus A, Müller MC, for the SAKK and the German CML
Study Group: Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia (2014). 1-5. PMID: 24798484

Hehlmann R, Hasford J, Pfirrmann M, Lauseker M, Saußele S, Hochhaus A: Reply to H. Kantarjian and Cortes. Journal of Clinical Oncology Vol 32, 2014. PMID: 25002729

Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb H-J, Hasford J, Saußele S, Hochhaus A: Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology 32 (5) 2014, 415-23. PMID: 24297946

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. (2014) 15, 1065-75. doi: 10.1016/S1470-2045(14)70330-4. PMID: 25088940

Hochhaus A: Optimizing tolerability of TKI therapy in CML. Blood, Vol 123, No 9. 1284-85. PMID:24578491

Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G: Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. Haematologica (2014). PMID: 24532039

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A: Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. (2014) 27, 1353-60. doi: 10.1182/blood-2013-06-510396.
PMID: 24335106

Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. (2014) 23, 494-500. doi: 10.1182/blood-2013-06-511592.
PMID: 24311723

Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A: Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. (2014) 55, 1451-62. doi: 10.3109/10428194.2013.845883.
PMID: 24050507

Jabbour E, Ottmann OG, Deininger M, Hochhaus A: Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica (2014) 99, 1. 7-18. PMID: 24425689

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R: Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Ann Hematol. (2014) 93, 71-80. doi: 10.1007/s00277-013-1937-4. PMID: 24162333

Klein S, Schmidt C, La Rosée P, Pletz M, Harz S, Dirsch O, Fritzenwanger M, Stallmach A:
Fulminant gastrointestinal bleeding caused by EBV-triggered hemophagocytic lymphohistiocytosis: report of a case. Z Gastroenterol. (2014)52, 354-9. doi: 10.1055/s-0034-1366154. PMID: 24718941

Kripp M, Willer A, Schmidt C, Pilz LR, Gencer D, Buchheidt D, Hochhaus A, Hofmann WK, Hofheinz RD: Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors. Ann Hematol. (2014) 93,317-25. doi: 10.1007/s00277-013-1861-7.
PMID: 23925929

La Rosée P: Therapie der chronischen myeloischen Leukämie nach Versagen der Erstlinientherapie: THIEME REFRESHER ONKOLOGIE (2014) 6, R37 - R52

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC: Equivalence of BCR‑ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol (2014). DOI 10.1007/s00432-014-1746-8. PMID: 24952896

Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. (2014) 201, 27-65. PMID: 24756784

Mayerhöfer T, Krafft C, Neugebauer U, Dochow S, Matthäus C, Kirsch M, Schackert G, Clement JH, Bauer M, Brehm BR, Popp J: Schnelle und schonende Aufklärung, Potenzial und Grenzen Raman-spektroskopischer Verfahren in der medizinischen Diagnostik. labor&more 3.14, 45-48.

Miranda MB, Hartmann JT, Al‑Batran S-E, Kripp M, Gencer D, Hochhaus A, Hofheinz R-D, Merx K: Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol (2014), 140, 829–837. PMID: 24556803

Mügge C, Liu R, Görls H, Gabbiani C, Michelucci E, Rüdiger N, Clement JH, Messori L, Weigand W: Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions. Dalton Trans. (2014) 28, 3072-86. doi: 10.1039/c3dt52284a. PMID: 24169734  

Neugebauer U, Kurz C, Bocklitz T, Berger T, Velten T, Clement JH, Krafft C, Popp J: Raman-Spectroscopy Based Cell Identification on a Microhole Array Chip: MICROMACHINES (2014) 5, 2014 - 2015

Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H: Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol (2014) 93, 1083–1095. PMID: 24777705

Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb H-J, Hasford J, Gratwohl A, Hehlmann R, for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group: Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. J Cancer Res Clin Oncol (2014) 140, 1367–1381. PMID: 24718719

Philipp M, Schwaab J, Dietz CT, Hanfstein B, Kalmanti L, Munjal U, Mossner M, Nowak D, Seifarth W, Hofmann WK, Hochhaus A, Müller MC, Erben P: Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). J Cancer Res Clin Oncol. (2014) 140, 411-7. doi: 10.1007/s00432-013-1579-x. PMID: 24390277

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann W-K, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S, for the German Chronic Myeloid Leukemia Study Group, and the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK): Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol (2014 93, 1167-1176. PMID: 24658964

Schilling K, Hochhaus A: Paraneoplastische Gerinnungsstörungen. Der Onkologe (2014) 20, 497–508.

Schmidt M, Rinke J, Schäfer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T: Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. (2014) 28, 2292-9. doi: 10.1038/leu.2014.272. PMID: 25212276 

Schnetzke U, Schrenk K, Spies-Weisshart B, Kunert C, Hochhaus A, Scholl S: Different clones of acute leukemia after successful treatment of Hodgkin’s disease. Ann Hematol (2014). DOI 10.1007/s00277-014-2095-z. PMID: 24801016

Schnetzke U, Fischer M, Frietsch JJ, Finkensieper A, Clement JH, Hochhaus A, La Rosée P: Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses track. Cytometry B Clin Cytom. (2014) 86, 229-35. doi: 10.1002/cyto.b.21091. PMID: 23576291

Schnetzke U, Fix P, Spies‑Weisshart B, Schrenk K, Glaser A, Fricke H-J, La Rosée P, Hochhaus A, Scholl S: Efficacy and feasibility of cyclophosphamide combined with intermediate‑ dose or high‑dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). J Cancer Res Clin Oncol (2014) 140, 1391–1397. PMID: 24728467

Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G: Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood (2014), Vol 123, No 15. 2317-24. PMID: 24569263

Stein BL, Swords R, Hochhaus A, Giles F: Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia (2014). doi: 10.1038/leu.2014.176. PMID: 24888274

Schwab KS, Hahn-Ast C, Heinz WJ, Germing U, Egerer G, Glasmacher A, Leyendecker C, Marklein G, Nellessen CM, Brossart P, von Lilienfeld-Toal M: Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection. (2014) 42, 97-104. doi: 10.1007/s15010-013-0524-x. PMID: 23979853

Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H: A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. (2014) 69, 3387-92. doi: 10.1093/jac/dku305. PMID: 25103492 

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela J-M, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim D-W, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, T Pajič , Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VHJ, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, M C Müller MC, Hochhaus A, Schimmel H, Cross NCP, Emons H: A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real time quantitative PCR. Leukemia (2014). doi: 10.1038/leu.2014.217. PMID: 25036192

Popp J, Mayerhöfer T, Krafft C, Neugebauer U, Dochow S, Matthäus C, Kirsch M, Schackert G, Clement JH, Bauer M, Brehm BR: Potenzial und Grenzen Raman-spektroskopischer Verfahren in der medizinischen Diagnostik. Labor&More 3 / 2014 

Theumer A, Gräfe C, Bähring F, Bergemann C, Hochhaus A, Clement JH: Superparamagnetic iron oxide nanoparticles exert different cytotoxic effects on cells grown in monolayer cell culture versus as multicellular as multicellular spheroids. JournalofMagnetismandMagneticMaterials(2014), http://dx.doi.org/10.1016/j. jmmm.2014.10.039i